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Purpose: In this study, we investigated the biochemical pharmacology of pirenoxine (PRX) and catalin under in vitro
selenite/calcium- and ultraviolet (UV)-induced lens protein turbidity challenges. The systemic effects of catalin were
determined using a selenite-induced cataractogenesis rat model.
Methods: In vitro cataractogenesis assay systems (including UVB/C photo-oxidation of lens crystallins, calpain-induced
proteolysis, and selenite/calcium-induced turbidity of lens crystallin solutions) were used to screen the activity of PRX
and catalin eye drop solutions. Turbidity was identified as the optical density measured using spectroscopy at 405 nm.
We also determined the in vivo effects of catalin on cataract severity in a selenite-induced cataract rat model. Sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was applied to analyze the integrity of crystallin
samples.
Results: PRX at 1,000 μM significantly delayed UVC-induced turbidity formation compared to controls after 4 h of UVC
exposure (p<0.05), but not in groups incubated with PRX concentrations of <1,000 μM. Results were further confirmed
by SDS–PAGE. The absolute γ-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of
catalin equivalent to 1~100 μM PRX in a concentration-dependent manner. Samples with catalin-formulated vehicle only
(CataV) and those containing PRX equivalent to 100 μM had a similar protective effect after 4 h of UVC exposure
compared to the controls (p<0.05). PRX at 0.03, 0.1, and 0.3 μM significantly delayed 10 mM selenite- and calcium-
induced turbidity formation compared to controls on days 0~4 (p<0.05). Catalin (equivalent to 32, 80, and 100 μM PRX)
had an initial protective effect against selenite-induced lens protein turbidity on day 1 (p<0.05). Subcutaneous pretreatment
with catalin (5 mg/kg) also statistically decreased the mean cataract scores in selenite-induced cataract rats on post-
induction day 3 compared to the controls (1.3±0.2 versus 2.4±0.4; p<0.05). However, catalin (equivalent to up to 100
μM PRX) did not inhibit calpain-induced proteolysis activated by calcium, and neither did 100 μM PRX.
Conclusions: PRX at micromolar levels ameliorated selenite- and calcium-induced lens protein turbidity but required
millimolar levels to protect against UVC irradiation. The observed inhibition of UVC-induced turbidity of lens crystallins
by catalin at micromolar concentrations may have been a result of the catalin-formulated vehicle. Transient protection by
catalin against selenite-induced turbidity of crystallin solutions in vitro was supported by the ameliorated cataract scores
in the early stage of cataractogenesis in vivo by subcutaneously administered catalin. PRX could not inhibit calpain-
induced proteolysis activated by calcium or catalin itself, and may be detrimental to crystallins under UVB exposure.
Further studies on formulation modifications of catalin and recommended doses of PRX to optimize clinical efficacy by
cataract type are warranted.
Cataracts have been a significant global problem of visual
impairment for centuries. It is estimated that the number of
cataract victims will increase by about one-third over the next
20 years, and that cataracts will remain the leading cause of
visual impairment in all regions of the world [1,2]. Without
intervention, the global number of individuals with cataracts
and other eye disorders will increase from 44 million in 2000
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to 76 million in 2020 [3]. Although cataracts can be surgically
cured, in some countries the treatment is unavailable. Cataract
prevention is, therefore, still important, and the discovery of
effective  anti-cataract  drugs  is  an  important  issue  in  eye
health.
Pirenoxine  (PRX),  a  pyridophenoxazine  compound
resembling  xanthommatin,  competitively  inhibits  the
sulfhydryl  combination  of  quinoid  substances  with  lens
proteins. Ogino et al. [4,5] proposed that the histopathology
of cataracts was caused by various quinoid substances. PRX
was first introduced in Japan in 1958 to prevent early cataracts,
and it is still widely used in Taiwan. Although PRX has been
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1862used clinically for many years [6-8], scientific evidence of its
efficacy  is  lacking.  A  2006  paper  criticized  doctors  for
prescribing PRX without such proof [9].
The  effectiveness  of  preparations  for  cataracts,
particularly PRX, should be verified before ophthalmologists
further  prescribe  them.  Although  some  PRX  studies  have
shown  beneficial  effects,  poor  design  (e.g.,  non-double
blinded,  insufficient  case  numbers,  and  short  follow-up
periods)  has  made  the  conclusions  questionable  [10].
Evidence-based  studies  are  still  needed  to  clarify  the
biochemical and clinical roles of PRX in preventing cataract
formation.
Risk  factors  for  cataract  formation  include  eye
inflammation,  environmental  hazards,  drug-induced  side-
effects, age, gender and genetic factors. Among the many risk
factors  associated  with  cataract  formation,  it  has  been
determined  that  various  ions  may  play  roles  in
cataractogenesis [11,12]. Our previous study established a
novel in vitro selenite ion-induced lens protein precipitation
system [13]. Selenite and calcium at the millimolar (mM)
level  have  been  demonstrated  to  cause  lens  crystallin
aggregation [13-15]. The ability of selenite to cause cataracts
in an animal model was first described in 1977 [16]. Selenite’s
involvement in cataract generation is related to raised levels
of  calcium  resulting  from  the  increased  lens  membrane
permeability occurring naturally in older patients.
The  results  of  tests  focusing  on  accumulated  75Se  in
soluble  and  insoluble  proteins  of  the  lens  [17]  and  the
development of cortical opacities in a medium containing
selenite [18] indicate that selenite enters the lens itself. The
accumulation  of  selenite  in  the  lens  may  cause  cataract
formation and explains the high selenium content [19,20] in
human  lenses  with  increased  opacity.  Opaque  lenses  also
show an accumulation of calcium [21,22]. An increase in
intracellular Ca2+ triggers calcium-activated enzymes such as
calpains. The incubation of soluble proteins from rat lens with
calpain  II  protease  caused  precipitation  of  β-crystallin
polypeptides,  which  then  cleaved  at  their  similar  NH2-
terminal extensions [23]. Another study also revealed that the
addition of the calpain II inhibitor, E64, prevented calpain-
induced crystallin proteolysis [24].
The  human  lens  absorbs  both  ultraviolet  A  (UVA,
320~400 nm) and ultraviolet B (UVB, 290~320 nm) rays and
transmits the visible spectrum. A positive correlation between
the prevalence of senile cataracts and levels of climatic UV
radiation was reported earlier [25], and the decreased lens
clarity may result from the high-molecular-weight disulfide-
linked proteins aggregating inside the aging human lens [26].
Oxidative stress also modifies protein disulfide formation in
the human lens [27]; for example, the observed increased
production  of  reactive  oxygen  species  (ROS),  decreased
glutathione level, and increased disulfide bonds and carbonyl
content in lenses further result in cross-linkage and insoluble
large-molecular protein precipitants, causing light scattering
after exposure to UVB [28]. Absorption of UVB by lens
molecules was also reported to lead to photo-oxidative stress
[29] and increased risk of cortical and subcapsular cataracts
[25,30].  Exposure  to  ultraviolet  C  (UVC,  200~290  nm)
changed the secondary structure and decreased the chaperone
activities  of  α-crystallins  [31,32],  resulting  in  increased
turbidity and free radicals [33].
PRX  with  selenite/calcium  ditopic  complexation  [14]
provides a rationale for using PRX-based catalin eye drops in
eye clinics. However, the role of PRX in catalin's effects on
selenite-,  calcium-,  and  UVB-induced  formation  of
crosslinked proteins and UVC overexposure-induced cataract
formation is still unknown. Therefore, to determine the role
of  pure  PRX  in  the  activities  of  catalin  eye  drops  and
formulation  effects,  this  study  employed  in  vitro
cataractogenesis assay systems of selenite/calcium-induced
precipitation, UVB/C photo-oxidation of lens crystallins, and
calpain-induced proteolysis to investigate the mechanisms of
the drug. The in vivo efficacy of catalin was then confirmed
in a selenite-induced cataractogenesis rat model.
METHODS
General: Porcine lenses were decapsulated and homogenized
in lens buffer containing 50 mM Tris-HCl, 0.1 M NaCl, 5 mM
EDTA, 0.01% β-mercaptoethanol, and 0.02% sodium azide,
at pH 8.0. After centrifugation at 16,060× g for 30 min, the
supernatant  was  collected,  and  the  protein  concentration
determined  according  to  the  Bradford  method  (BioRad
Laboratories, Irvine, CA). Pure PRX was purchased from
Hangzhou Dayangchem (Hangzhou, Zhejiang, China), and
catalin was from Kaken Pharmaceutical (Tokyo, Japan). To
determine the dosing efficacy of the catalin eye drop solution
against cataract formation induced by various pathological
factors, catalin solutions were used and prepared according to
instructions, with one exception; the volume of the vehicle
solvent used was minimized to conform to the study design.
PRX doses (16~100 μM) of catalin product powder for the in
vitro assay were calculated according to the labeled PRX
content of catalin and to clinically recommended doses for
humans. Samples for the turbidity assay were incubated at
37 °C using microtiter plates (MicrotestTM 96; Falcon; Fisher
Scientific, Franklin Lakes, NJ), and turbidity was measured
as the optical density (OD) at 405 nm, using an enzyme-linked
immunosorbent  assay  (ELISA)  reader  (Tecan  SunriseTM;
Tecan Group, Männedorf, Switzerland).
Photo-oxidation of γ-crystallins by UVB or UVC in vitro:
Chemical modifications or oxidation of lens proteins by UV
irradiation may also contribute to opacities and were shown
to cause the turbidity of γ-crystallin [34,35]. In this anti-UVB
assay, 200 µl of incubation lens buffer mixtures containing
20 mg/ml γ-crystallin, with or without various concentrations
of PRX (0, 0.1, 1, 10, or 100 μM) were exposed to UVB
(Vilber Loumat bio-link crosslinker; 312 nm) for 0, 2, 4, and
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200 µl of incubation lens buffer mixtures containing 0.4 mg/
ml γ-crystallin, with or without various concentrations of PRX
(0,  10−3,  10−2,  0.1,  0.3,  and  1  mM),  or  catalin  eye  drops
equivalent to up to 100 μM PRX, were exposed to UVC (UVP
CL-1000;  254  nm)  for  0,  1,  2,  3,  and  4  h.  After  the
measurement, the mixture from each well was collected for a
sodium dodecylsulfate PAGE (SDS–PAGE) analysis.
m-Calpain-induced proteolysis of crystallins: To determine
the in vitro exogenous calpain-induced lens protein turbidity,
exogenous  lens  calpain  was  activated  by  adding  1.5  mM
calcium to induce exogenous calpain II, as modified from the
Shih et al. [37] study. Incubations at 200 µl were prepared by
adding 5 mg of lens-soluble proteins/ml, 7.5 units calpain II
(from porcine kidney; Calbiochem, Torrey Pines, CA) with
100 μM PRX, various concentrations of catalin, (16, 32, 80,
and 100 μM), or catalin-formulated vehicle only (CataV),
while 3 mM EDTA or 100 μM E64 was used as the positive
control. Proteolysis was initiated by adding 1.5 mM Ca2+,
processed for 10 min at 37 °C, and was terminated by the
addition of EDTA to a final concentration of 3 mM. Protein
patterns were then analyzed by SDS–PAGE.
In vitro lens crystallin turbidity assays induced by 10 mM
selenite  or  calcium:  The  crystallin  turbidity  assays  were
performed by adding sodium selenite [13] or calcium ions
[38] to cause lens turbidity. The incubation lens buffer mixture
at 200 µl contained 50 mg/ml of lens-soluble proteins, with or
without various concentrations of PRX (0, 0.03, 0.1, 0.3, and
1  μM)  or  a  catalin  eye  drop  solution  containing  PRX
equivalent to 0, 0.03, 0.1, 0.3, and 1 μM. Selenite or calcium
at 10 mM was then added to induce turbidity. The absolute
OD and changes in the OD were calculated for each incubation
day and treatment.
Selenite-induced  cataract  animal  model:  The  ability  of
selenite  to  cause  cataracts  in  an  animal  model  was  first
described in 1977 [16]. Sprague-Dawley rat pups, aged 9 days,
were obtained from The National Science Council Animal
Center (Taipei, Taiwan) and housed with their mothers under
standard  conditions.  All  experiments  were  performed  in
accordance with the Institute for Laboratory Animal Research
Guide for the Care and Use of Laboratory Animals. The rat
pups  were  given  normal  rat  chow  and  water  ad  libitum.
Beginning from postnatal day 11, rat pups were divided into
four groups (n=3~7) and administered subcutaneous catalin
solutions (0, 2.5, or 5 mg/kg) or the vehicle for 3 days. On
postnatal day 14, all pups were given a single injection of
19 μmol/kg sodium selenite (pH 9.0) subcutaneously except
those with no treatment (normal controls). To minimize bias,
the transparency status of all eyes was observed daily by an
ophthalmologist, who was blind to the treatment protocols,
using slip lamp to score on a 4-point scale: 0 (extremely clear),
1  (diffuse  scattered  nuclear  opacities),  2  (formation  of
pinpoint cataracts), and 3 (mature dense opacities involving
the  entire  lens)  [39].  Mean  transparency  scores  were
calculated for each group, and the lenses were then collected
at the end of the experiment. Lens proteins were extracted and
centrifuged at 15,000× g and 4 °C for 15 min to obtain the
supernatant and insoluble pellets for the SDS–PAGE analysis.
Statistical analysis: Average turbidity formation in absolute
OD, changes from the baseline or percentage changes versus
the controls. The cataract scores after various treatments, are
expressed as the mean±standard error of the mean (n≥3). The
scores were statistically analyzed using an unpaired  t-test
between two groups, or by Kruskal–Wallis one-way ANOVA
on ranks with post-hoc Dunn’s test, using SigmaStat 2.03
(Systat Software, San Jose, CA). Differences were considered
significant when the p value was <0.05.
RESULTS
Effects of PRX and catalin on UVB- and UVC-induced photo-
oxidation of γ-crystallins: UV irradiation is a significant risk
factor for cataractogenesis. After 6 h of UVB exposure, none
of the concentrations of PRX (0.1, 1, 10, or 100 μM) inhibited
or delayed turbidity formation. In fact, turbidity in the PRX
groups was even higher than in the controls. However, a high
concentration of PRX (1 mM) inhibited turbidity formation
induced by 4 h of UVC exposure. There was a significant
statistical difference in the OD changes between the control
and PRX groups (0.489±0.007 versus 0.401±0.015, p<0.05).
These results showed that at a high concentration (1 mM),
PRX  may  protect  γ-crystallin  from  continuous  insults  by
UVC. Therefore, PRX delayed turbidity formation induced by
UVC but not by UVB (data not shown).
Patterns of γ-crystallin in the control group showed that
protein expression significantly decreased at 21 kDa. These
results demonstrate that γ-crystallin was degraded by UVC
exposure (Figure 1A). Patterns of γ-crystallin in groups with
higher concentrations of PRX were more similar to normal
ones. Similar results were also observed for catalin solutions
(Figure 1B).
Catalin  containing  PRX  equivalents  of  16~100  μM
significantly  ameliorated  the  turbidity  of  lens  crystallins
following 4 h of UVC exposure in a concentration-dependent
manner  compared  to  the  controls  (p<0.05).  Samples
containing  only  catalin  formulated  vehicle  had  similar
potencies  of  anti-UVC  activity  to  those  containing  PRX
equivalent to 100 μM.
PRX or catalin failed to inhibit m-calpain-induced proteolysis
of crystallins: SDS–PAGE (Figure 2) of the control group
showed  there  was  a  decrease  in  29-kDa  proteins  and  an
increase in 19-kDa proteins compared to normal samples,
which indicated that β- and α-crystallins were degraded by
exogenous calpain II, which was activated by calcium in this
assay system. Figure 2 shows that presence of catalin or PRX
changed  the  protein  patterns  in  SDS–PAGE,  since  no
difference was found in the control with the PRX (100 μM)
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100 μM PRX), while no truncated 19-kDa proteins appeared
in the positive control groups (EDTA, E64).
Effect of PRX against 10 mM selenite- and calcium-induced
lens protein turbidity: The OD of the selenite control group
increased to 0.57 while those for the 0.03, 0.1, and 0.3 μM
PRX  treatment  groups  exhibited  significantly  smaller
increases as shown in Figure 3A (p<0.05). In the calcium-
induced turbidity assays on day 4, the absolute changes in OD
from day 0 for the control and various concentrations of PRX
(0.03, 0.1, and 0.3 μM) groups are shown in Figure 3B, and
all PRX groups had statistically significantly smaller turbidity
changes  compared  to  the  controls  (p<0.05).  Various
Figure  1.  Photo-protection  against  4  h  of  ultraviolet  C  (UVC)
exposure by pirenoxine (PRX) and catalin. A: A 12% SDS–PAGE
of γ-crystallins incubated with or without PRX (0~1000 μM). M,
Bioladder® protein marker; lane 1, normal; 2, control; 3, 1 μM PRX;
4, 10 μM PRX; 5, 100 μM PRX; 6, 300 μM PRX; 7, 1000 μM PRX.
The protein bands in Lane 7 was similar to lane 1 (normal). B:
Turbidity  expressed  as  optical  density  (OD)  was  determined  by
spectroscopy at 405 nm. The y-axis indicates the OD of γ-crystallins
incubated with various doses of catalin. B16: catalin containing 16
μM  PRX,  B32:  catalin  equivalent  to  32  μM  PRX,  B80:  catalin
equivalent to 80 μM PRX, B100: catalin equivalent to 100 μM PRX,
CataV:  catalin-formulated  vehicle  only.  *p<0.05  versus  control
(Ctrl) group.
concentrations  of  PRX  (0.03~0.3  μM)  inhibited  turbidity
formation in a dose-dependent manner against selenite- and
calcium-induced turbidity of lens crystallins.
Catalin  delayed  selenite-induced  turbidity  formation  of
crystallin solutions in vitro and in a cataract model of rats:
The  protective  effects  of  catalin  solutions  containing
0.016~0.1 μM PRX against selenite-induced precipitations
were assayed. Percentages of the OD for groups incubated
with the catalin-formulated vehicle were obtained by dividing
by the ones for the selenite-only controls; the results were
88.3%~98.6%, as shown in Figure 4A. Turbidity formation
was significantly delayed in groups incubated with catalin
containing 0.032~0.1 μM PRX on incubation day 1, compared
to  the  controls  (p<0.05).  The  efficacy  of  catalin  against
selenite insults was further studied in the selenite-induced
cataract rat model. The average cataract scores of the control
(selenite  only)  and  5  mg/kg  catalin-treated  group  on
postinduction day 3 were 2.4±0.4 and 1.3±0.2, respectively
(p<0.05), as shown in Figure 4B. There was no significant
difference  in  opacity  scores  after  post-induction  day  4  in
groups treated with catalin (2.5 and 5 mg/kg), compared to the
controls. Results indicated that catalin may delay cataract
formation. SDS–PAGE analysis (Figure 5A) showed catalin
treatment decreased lens protein degradation in the fraction of
water-soluble proteins; however, catalin at 5 mg/kg preserved
20-  and  26-kDa  proteins  similar  to  normal  lens  proteins,
particularly water-soluble ones (Figure 5A). In Figure 5B,
fewer 31-kDa proteins were seen in selenite injected rat lenses
and increased insoluble proteins in the 21–25 kDa. Catalin
pretreatment slightly protected water-insoluble lens proteins.
DISCUSSION
Higher levels of calcium ions in human lenses with cortical
cataracts indicate a possible role in opacification [40,41]. The
Figure  2.  Effects  of  various  treatments  on  calpain-induced  lens
proteolysis. A 12% SDS–PAGE analysis shows that proteolyzed
proteins were seen at 19 kDa (lane 2–6, lane 9) while EDTA and
calpain inhibitor E64 inhibited proteolysis. M, Fermentas prestained
protein ladder® marker; lane 1, normal; 2, control; 3, 100 μM PRX;
4, catalin equivalent to 100 μM PRX; 5, catalin equivalent to 80 μM
PRX; 6, catalin equivalent to 32 μM PRX; 7, 3 mM EDTA; 8, 100
μM E64; 9, catalin-formulated vehicle only.
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animal models was correlated to proteolysis of lens crystallins
[42-44]. This increase causes lens turbidity [38] by activating
calpain, a protease present in the lens. Cataracts are well
known to result from proteolysis of lens crystallins [42-44],
lens crystallin aggregation [45], calcium-activated calpain-
induced  lens  turbidity  [15,46],  and  selenite-induced  lens
protein turbidity [13]. Both Wu et al. [15] and Chen et al.
[47] reported that the ability to chelate calcium could be an
important  factor  in  preventing  cataracts.  Followed  by  our
previous chemistry study for PRX [14], this study shows dose-
dependent anti-cataract effect of PRX (0.03~0.3 μM; Figure
3)  against  selenite/calcium-induced  turbidity  formation.
Figure  3.  Pirenoxine  (PRX)  ameliorated  selenite-  and  calcium-
induced lens protein turbidity. Turbidity was expressed as an optical
density (OD) and was determined by spectroscopy at 405 nm for 4
days. *0.03, 0.1, and 0.3 μM PRX versus controls (selenite or calcium
only) at p<0.05. A: Selenite-induced turbidity formation in terms of
the absolute OD was plotted versus incubation days. B: Calcium-
induced turbidity formation expressed as absolute changes in lens
turbidity in terms of the OD from the baseline were plotted by
incubation day.
Catalin eye drop solution equivalent to 0.032–0.1 μM (Figure
4A) also ameliorated selenite-induced turbidity.
In addition to the above-mentioned factors, UV-induced
oxidative damage is highly correlated with cataractogenesis
[48,49]. Among five regions of solar radiation, UVC and UVB
are responsible for photochemical reactions. This study is the
first report to show that PRX up to 0.1 mM did not protect γ-
crystallins  [50],  a  fraction  of  lens  proteins  sensitive  to
oxidation,  against  UVB-induced  photo-oxidation,  but  that
PRX at 1 mM did protect γ-crystallins against UVC irradiation
Figure 4. Effect of catalin on selenite-induced lens turbidity and
cataract scores. A: Percentages of the optical density (OD) for lens
turbidity of the selenite -only group influenced by the presence of
catalin equivalent to 0.016–0.1 μM PRX or the catalin formulated
vehicle  (CataV)  were  compared.  Turbidity  was  determined  by
spectroscopy at 405 nm. *catalin (0.032–0.1 μM PRX) versus CataV
at p<0.05. B: Average cataract scores of groups treated with various
doses  of  catalin  in  a  selenite-induced  cataract  rat  model.  Rats
(n=6~20) pretreated with catalin solutions (0, 2.5, and 5 mg/kg) or
the CataV administered subcutaneously for 4 days. Each lens cataract
score was classified into four degrees (0–3) from clear to mature
dense. The average cataract score of each group is expressed as the
mean±standard error and is plotted versus the post cataract induction
day. *catalin (5 mg/kg) versus Se controls at p<0.05.
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UVB as in the Ciuffi et al. [51] cornea study, but our assay
system  was  more  similar  to  a  study  of  UVB-induced  γ-
crystallin turbidity [36]. Our negative results for PRX may
have been due to the fact that our assay system used prolonged
UVB exposure times of up to 2~6 h and accumulated 30 times
the UVB insults (~24 J) of those used in the Ciuffi et al. [51]
cornea  study  (up  to  0.8  J).  Therefore,  doses  of  PRX
(0.1~100 μm) used in the current study were insufficient to
protect against UVB insults. Furthermore, the stability of PRX
under UVB exposure is unclear. Pyridophenoxazine of PRX
consists of two moieties of 3-hydroxykynurenin, a known
photosensitizer which increases lens crystallin aggregation
with  UVB  exposure  [52].  PRX  was  thought  to  form  3-
hydroxykynurenin after UVB irradiation, in turn enhancing
protein aggregation; this was indeed observed in the current
study.
Even though UVC can be blocked by the atmosphere or
ozone layer, environmental changes can lead to increased
exposure to UVC. The observed anti-UVC results in those
incubations with catalin solutions containing PRX at up to
Figure 5. SDS–PAGE analysis of selenite-induced rat lenses treated
with catalin equivalent to 2.5 and 5 mg/kg pirenoxine (PRX). M,
marker; lane 1, normal; lane 2, control (Se only); lane 3, Se+catalin
formualted vehicle; lane 4–5, Se+catalin equivalent to 2.5 mg/kg
PRX; lane 6–7, Se+catalin equivalent to 5 mg/kg PRX. Duplicated
samples from different lenses of rats pretreated by different catalin
doses were analyzed. A: A 12.5% SDS–PAGE of soluble fractions
of lenses and Amersham Rainbow Marker were used. Red arrow, 20-
kDa proteins; red box, more preserved 20-kDa proteins in catalin-
treated rats; green box, preserved 26-kDa proteins. B: A 20% SDS–
PAGE of insoluble lens fractions and Fermentas SM0441 Marker
were used. Blue box, 31 kDa proteins; red box, 21–25 kDa; black
box, proteolytic fragments.
~100  μM  indicated  that  CataV  contains  other  ingredients
which may also provide anti-UVC activity, resulting in extra
photoprotection.  However,  since  our  catalin  solution
containing 100 μM PRX was prepared by dissolving catalin
powder, the protective effect of a catalin solution containing
100 μM PRX appeared to have been due to CataV. The dose-
dependent results shown in Figure 2B may have been due to
the serial dilution of CataV. Therefore, the catalin eye drop
solution provided anti-UVC protection due to PRX and other
components. Similar to the results described in our earlier
study of coumarins, UVC irradiation for 2~6 h resulted in
increased turbidity and decreased protein bands at 21 kDa.
The observed results may have been due to the insult of free
radicals  on  γ-crystallins  that  further  modified  the  protein
structures [32]. The presence of 1 mM PRX protected  γ-
crystallins irradiated with UVC. The mechanism may be due
to  the  radical-scavenging  activity  of  PRX  [53,54]  against
UVC-induced free radicals, singlet oxygen, and superoxides.
Concentrations of PRX and catalin which ameliorated
lens protein turbidity formation were at micromolar levels,
similar to those used in the Cantore et al. [55] cornea culture
study; however, results in Figure 2 demonstrate that PRX,
even up to 100 μM, did not inhibit calpain proteolysis. These
results indicate that the mechanisms for this activity against
selenite-induced turbidity may be only partially related to the
chelating of calcium and selenite in 1: 3 and 1: 6 ratios,
respectively, reported in our earlier study [14], because the
chosen levels (0.03~100 μM) of PRX (Figure 3A,B and Figure
4A)  were  only  trapping  up  to  0.09~600  μM  calcium  and
selenite cations according to the reported chelation ratios,
which are much smaller than the 10 mM of selenite/calcium
used.  This  may  account  for  the  observed  initial  in  vitro
protective results, instead of sustained activity compared to
CataV. An additional reason why 100 μM PRX did not inhibit
calpain activation by 1.5 mM calcium was that PRX itself may
have less affinity for calcium compared to calpain. In addition,
PRX or components of catalin, unlike E64, might not be able
to  directly  bind  to  calpain  to  inhibit  calpain  activity.
Clarification regarding other mechanisms for protecting lens
proteins against selenite-induced turbidity remains for future
investigations.
The initial protective effects were further confirmed by
the  early  protection  from  cataract  formation  following
systemic catalin (5 mg/kg) given for 3 days before cataract
induction  on  post-induction  day  3  in  a  selenite-induced
cataract rat model (Figure 4B). Such results are consistent
with suggestion made by the majority of exponents of catalin,
that catalin is useful only in an early stage of human cataract
formation,  but  no  medical  therapy  effect  of  catalin  was
reported from a clinical trial study by Angra et al. [56]. Our
data using an intravitreal injection of a catalin solution (1 mg/
ml equivalent to the clinically recommended maximum daily
dose of 0.025 mg) following selenite injection also showed no
significant differences in opacity scores of post-induction day
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18675 (data not shown). Therefore, catalin seems to be useful in
cataract prevention, but not for therapy.
The initial beneficial effect of catalin not persisting for
more than 4 days may have been due to catalin administration
being discontinued after selenite induction. Inadequate doses
of catalin (2.5~5 mg/kg) used in the current study might also
account  for  the  results,  since  a  higher  dose  (20  mg/kg,
intraperitoneally) of PRX, which inhibited alloxan-induced
diabetic cataractogenesis, was given daily for 6 weeks [8]. A
small protective effect of catalin at post-induction day 4 was
also seen in the Ito et al. [57] study, in which 0.24 mg/ml of
catalin (four instillations daily) was chosen. It was speculated
that  more-frequent  systemic  dosing  following  cataract
induction  by  selenite  may  provide  better  protection  from
cataractogenesis.
Soluble fractions analyzed by SDS–PAGE after various
treatments in vivo indicated that samples from rats treated
with 5 mg/kg PRX were similar to normal ones. The more
preserved in 20 and 26 kDa protein bands, suggested as αA-
crystallins  and  β-crystallins,  were  seen  in  samples  from
individual rats with less severe cataract formation after catalin
pretreatments, as reported in a lenticular protein profile of
selenite-induced cataractogeneis [58]. The observed increase
in new proteins, which ranged between 21 and 25 kDa and
below 20 kDa (Figure 5B) in the insoluble fractions, may have
been due to hydrolysis of 20, 26, and 27 kDa as reported during
selenite  cataractogeneis  [42,59].  The  loss  of  31  kDa  β-
crystallin and the accumulation of polypeptides below 31 and
19  kDa  of  the  insoluble  fractions  in  rats  with  cataract
development  were  similar  to  the  results  of  Tamada  et  al.
[60].
In conclusion, PRX protected crystallins against UVC-,
selenite-,  and  calcium-induced  lens  protein  turbidity;
however,  it  might  be  detrimental  under  UVB  exposure.
Catalin may be useful in ameliorating UVC-induced turbidity
formation, but not in inhibiting calpain-induced proteolysis of
lens crystallins in vitro. The transient protection by catalin
against selenite-induced turbidity of crystallin solutions in
vitro was supported by the ameliorated cataract scores in the
early stage of cataractogenesis in vivo by subcutaneously
administered catalin. Modification of the catalin-formulated
vehicle  is  recommended  to  improve  its  overall  protective
effects against the cataract-induction factors presented here.
Further studies are warranted to assess the clinical efficacy
and optimal doses of PRX of catalin to ameliorate various
types of cataract development.
ACKNOWLEDGMENTS
This work was supported by grants from The National Science
Council (Taiwan) and the Shin Kong Wu Ho-Su Memorial
Hospital (SKH-TMU-96–14). The providers of funds had no
role in the gathering or interpretation of the data, or in the
analysis or presentation of the results. The authors have no
commercial interests or conflicts of interest to disclose. The
manuscript was not previously presented at any meetings or
in any other form.
REFERENCES
1. Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R,
Etya'ale D, Negrel AD, Resnikoff S. 2002 global update of
available  data  on  visual  impairment:  a  compilation  of
population-based prevalence studies. Ophthalmic Epidemiol
2004; 11:67-115. [PMID: 15255026]
2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram
R,  Pokharel  GP,  Mariotti  SP.  Global  data  on  visual
impairment in the year 2002. Bull World Health Organ 2004;
82:844-51. [PMID: 15640920]
3. Frick KD, Foster A. The magnitude and cost of global blindness:
an  increasing  problem  that  can  be  alleviated.  Am  J
Ophthalmol 2003; 135:471-6. [PMID: 12654362]
4. Ogino S, Tojo H, Fujishige I, Katumori Y. Biochemical studies
on cataract. IX. Contribution to the histopathology of cataract
caused  by  various  quinoid  substances.  Am  J  Ophthalmol
1957; 44:94-105. [PMID: 13435332]
5. Ogino S, Yasukura K. Biochemical studies on cataract. VI.
Production of cataracts in guinea pigs with dinitrophenol. Am
J Ophthalmol 1957; 43:936-46. [PMID: 13424619]
6. Kociecki  J,  Zalecki  K,  Wasiewicz-Rager  J,  Pecold  K.
Evaluation of effectiveness of Catalin eyedrops in patients
with presenile and senile cataract Polish. Klin Oczna 2004;
106:778-82. [PMID: 15787181]
7. Chandorkar  AG,  Albal  MV,  Bulakh  PM,  Jain  PK.
Hypoglycaemic effect of 'Catalin' an anti-cataract agent in
rabbits, (a preliminary study). Indian J Ophthalmol 1978;
26:6-8. [PMID: 711283]
8. Bulakh PM, Chandorkar AG, Balsara JJ, Ranade SM, Albal
MV.  Effect  of  'catalin'  an  anticataract  agent  on  alloxan
induced hyperglycaemia and diabetic cataract in rats. Indian
J Ophthalmol 1980; 28:1-3. [PMID: 7203589]
9. Sekimoto M, Imanaka Y, Kitano N, Ishizaki T, Takahashi O.
Why are physicians not persuaded by scientific evidence? A
grounded  theory  interview  study.  BMC  Health  Serv  Res
2006; 6:92. [PMID: 16872522]
10. Murata  T.  Double  blind  study  on  the  effectiveness  of  a
pirenoxine eye drop to senile cataract in Japanese. Nippon
Ganka Kiyo 1980; 31:1217-22.
11. Dilsiz N, Olcucu A, Atas M. Determination of calcium, sodium,
potassium and magnesium concentrations in human senile
cataractous  lenses.  Cell  Biochem  Funct  2000;  18:259-62.
[PMID: 11180288]
12. Garner MH, Kuszak JR. Cations, oxidants, light as causative
agents in senile cataracts. P R Health Sci J 1993; 12:115-22.
[PMID: 8210282]
13. Liao JH, Chen CS, Maher TJ, Liu CY, Lin MH, Wu TH, Wu
SH.  Astaxanthin  interacts  with  selenite  and  attenuates
selenite-induced cataractogenesis. Chem Res Toxicol 2009;
22:518-25. [PMID: 19193053]
14. Liao JH, Chen CS, Hu CC, Chen WT, Wang SP, Lin IL, Huang
YH,  Tsai  MH,  Wu  TH,  Huang  FY,  Wu  SH.  Ditopic
complexation  of  selenite  anions  or  calcium  cations  by
pirenoxine: an implication for anti-cataractogenesis. Inorg
Chem 2011; 50:365-77. [PMID: 21138325]
15. Wu TH, Liao JH, Hou WC, Huang FY, Maher TJ, Hu CC.
Astaxanthin protects against oxidative stress and calcium-
Molecular Vision 2011; 17:1862-1870 <http://www.molvis.org/molvis/v17/a203> © 2011 Molecular Vision
1868induced porcine lens protein degradation. J Agric Food Chem
2006; 54:2418-23. [PMID: 16536628]
16. Ostádalová I, Babicky A, Obenberger J. Cataract induced by
administration of a single dose of sodium selenite to suckling
rats. Experientia 1978; 34:222-3. [PMID: 624358]
17. Shearer TR, Anderson RS, Britton JL. Uptake and distribution
of radioactive selenium in cataractous rat lens. Curr Eye Res
1982-1983; 2:561-4. [PMID: 7184708]
18. Gupta SK, Trivedi D, Srivastava S, Joshi S, Halder N, Verma
SD.  Lycopene  attenuates  oxidative  stress  induced
experimental cataract development: an in vitro and in vivo
study. Nutrition 2003; 19:794-9. [PMID: 12921892]
19. Dawczynski J, Winnefeld K, Konigsdorffer E, Augsten R, Blum
M,  Strobel  J.  Klin  Monatsbl  Augenheilkd  2006;
223:675-80. [PMID: 16927224]Selenium and cataract–risk
factor or useful dietary supplement?
20. Tarwadi K, Agte V. Linkages of antioxidant, micronutrient, and
socioeconomic status with the degree of oxidative stress and
lens  opacity  in  Indian  cataract  patients.  Nutrition  2004;
20:261-7. [PMID: 14990266]
21. Ciaralli  L,  Giordano  R,  Costantini  S,  Sepe  A,  Cruciani  F,
Moramarco  A,  Antonelli  B,  Balacco-Gabrieli  C.  Element
concentrations and cataract: an experimental animal model. J
Trace Elem Med Biol 2001; 14:205-9. [PMID: 11396778]
22. Rasi V, Costantini S, Moramarco A, Giordano R, Giustolisi R,
Balacco  Gabrieli  C.  Inorganic  element  concentrations  in
cataractous  human  lenses.  Ann  Ophthalmol  1992;
24:459-64. [PMID: 1485742]
23. David LL, Shearer TR. Beta-crystallins insolubilized by calpain
II in vitro contain cleavage sites similar to beta-crystallins
insolubilized during cataract. FEBS Lett 1993; 324:265-70.
[PMID: 8405363]
24. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Shearer TR.
Calpain-induced  light  scattering  by  crystallins  from  three
rodent  species.  Exp  Eye  Res  1997;  65:757-70.  [PMID:
9441699]
25. Hollows F, Moran D. Cataract–the ultraviolet risk factor. Lancet
1981; 2:1249-50. [PMID: 6118668]
26. Spector  A,  Roy  D.  Disulfide-linked  high  molecular  weight
protein associated with human cataract. Proc Natl Acad Sci
USA 1978; 75:3244-8. [PMID: 277922]
27. Lou MF, Dickerson JE Jr. Protein-thiol mixed disulfides in
human lens. Exp Eye Res 1992; 55:889-96. [PMID: 1486943]
28. Wu K, Kojima M, Shui YB, Sasaki K, Hockwin O. In vitro UV-
B effect on lens protein solutions. Ophthalmic Res 1997;
29:75-82. [PMID: 9154533]
29. McCarty  CA,  Taylor  HR.  Recent  developments  in  vision
research: light damage in cataract. Invest Ophthalmol Vis Sci
1996; 37:1720-3. [PMID: 8759338]
30. Zigman  S.  Environmental  near-UV  radiation  and  cataracts.
Optom Vis Sci 1995; 72:899-901. [PMID: 8749337]
31. Sommerburg O, Ullrich O, Sitte N, von Zglinicki D, Siems W,
Grune  T.  Dose-  and  wavelength-dependent  oxidation  of
crystallins by UV light–selective recognition and degradation
by  the  20S  proteasome.  Free  Radic  Biol  Med  1998;
24:1369-74. [PMID: 9641254]
32. Fujii N, Uchida H, Saito T. The damaging effect of UV-C
irradiation  on  lens  alpha-crystallin.  Mol  Vis  2004;
10:814-20. [PMID: 15534584]
33. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA:
relation to species metabolic rate and life span. Proc Natl Acad
Sci USA 1988; 85:2706-8. [PMID: 3128794]
34. Lee JS, Liao JH, Wu SH, Chiou SH. alpha-Crystallin acting as
a  molecular  chaperone  against  photodamage  by  UV
irradiation.  J  Protein  Chem  1997;  16:283-9.  [PMID:
9188067]
35. Liao  JH,  Lee  JS,  Chiou  SH.  Distinct  roles  of  alphaA-  and
alphaB-crystallins under thermal and UV stresses. Biochem
Biophys Res Commun 2002; 295:854-61. [PMID: 12127973]
36. Andley  UP,  Clark  BA.  Spectroscopic  studies  on  the
photooxidation of calf-lens gamma-crystallin. Curr Eye Res
1988; 7:571-9. [PMID: 3402245]
37. Shih M, David LL, Lampi KJ, Ma H, Fukiage C, Azuma M,
Shearer TR. Proteolysis by m-calpain enhances in vitro light
scattering by crystallins from human and bovine lenses. Curr
Eye Res 2001; 22:458-69. [PMID: 11584346]
38. Shearer TR, Ma H, Fukiage C, Azuma M. Selenite nuclear
cataract: review of the model. Mol Vis 1997; 3:8. [PMID:
9238097]
39. Geraldine P, Sneha BB, Elanchezhian R, Ramesh E, Kalavathy
CM,  Kaliamurthy  J,  Thomas  PA.  Prevention  of  selenite-
induced  cataractogenesis  by  acetyl-L-carnitine:  an
experimental study. Exp Eye Res 2006; 83:1340-9. [PMID:
16962580]
40. Rhodes  JD,  Sanderson  J.  The  mechanisms  of  calcium
homeostasis and signalling in the lens. Exp Eye Res 2009;
88:226-34. [PMID: 19061888]
41. Duncan G, Bushell AR. Ion analyses of human cataractous
lenses. Exp Eye Res 1975; 20:223-30. [PMID: 1122997]
42. David LL, Shearer TR. Calcium-activated proteolysis in the
lens  nucleus  during  selenite  cataractogenesis.  Invest
Ophthalmol Vis Sci 1984; 25:1275-83. [PMID: 6386740]
43. Sanderson J, Marcantonio JM, Duncan G. A human lens model
of  cortical  cataract:  Ca2+-induced  protein  loss,  vimentin
cleavage and opacification. Invest Ophthalmol Vis Sci 2000;
41:2255-61. [PMID: 10892870]
44. Marcantonio  JM,  Duncan  G,  Rink  H.  Calcium-induced
opacification and loss of protein in the organ-cultured bovine
lens. Exp Eye Res 1986; 42:617-30. [PMID: 3087764]
45. Sharma Y, Rao CM, Narasu ML, Rao SC, Somasundaram T,
Gopalakrishna A, Balasubramanian D. Calcium ion binding
to delta- and to beta-crystallins. The presence of the “EF-
hand”  motif  in  delta-crystallin  that  aids  in  calcium  ion
binding. J Biol Chem 1989; 264:12794-9. [PMID: 2753888]
46. Nakamura Y, Fukiage C, Azuma M, Shearer TR. Oxidation
enhances calpain-induced turbidity in young rat lenses. Curr
Eye Res 1999; 19:33-40. [PMID: 10415455]
47. Chen CS, Wu SH, Wu YY, Fang JM, Wu TH. Properties of
astaxanthin/Ca2+ complex formation in the deceleration of
cis/trans  isomerization.  Org  Lett  2007;  9:2985-8.  [PMID:
17629283]
48. Davies MJ, Truscott RJ. Photo-oxidation of proteins and its role
in  cataractogenesis.  J  Photochem  Photobiol  B  2001;
63:114-25. [PMID: 11684458]
49. Brian G, Taylor H. Cataract blindness–challenges for the 21st
century. Bull World Health Organ 2001; 79:249-56. [PMID:
11285671]
Molecular Vision 2011; 17:1862-1870 <http://www.molvis.org/molvis/v17/a203> © 2011 Molecular Vision
186950. Skouri-Panet F, Bonnete F, Prat K, Bateman OA, Lubsen NH,
Tardieu A. Lens crystallins and oxidation: the special case of
gammaS. Biophys Chem 2001; 89:65-76. [PMID: 11246746]
51. Ciuffi M, Pisanello M, Pagliai G, Raimondi L, Franchi-Micheli
S, Cantore M, Mazzetti L, Failli P. Antioxidant protection in
cultured corneal cells and whole corneas submitted to UV-B
exposure. J Photochem Photobiol B 2003; 71:59-68. [PMID:
14705640]
52. Bando M, Mikuni I, Obazawa H. Acceleration of calcium-
induced  aggregation  of  rat  lens  soluble  protein  by
photosensitization with 8-methoxypsoralen and 3-hydroxy-
L-kynurenine  O-beta-glucoside.  Exp  Eye  Res  1982;
34:953-60. [PMID: 7084352]
53. Ciuffi  M,  Neri  S,  Franchi-Micheli  S,  Failli  P,  Zilletti  L,
Moncelli MR, Guidelli R. Protective effect of pirenoxine and
U74389F on induced lipid peroxidation in mammalian lenses.
An in vitro, ex vivo and in vivo study. Exp Eye Res 1999;
68:347-59. [PMID: 10079143]
54. Boldyrev AA. Carnosine and free-radical defence mechanisms.
Trends Neurosci 1994; 17:468. [PMID: 7531887]
55. Cantore  M,  Siano  S,  Coronnello  M,  Mazzetti  L,  Franchi-
Micheli S, Boldrini E, Ciuffi M, Failli P. Pirenoxine prevents
oxidative effects of argon fluoride excimer laser irradiation in
rabbit corneas: biochemical, histological and cytofluorimetric
evaluations.  J  Photochem  Photobiol  B  2005;  78:35-42.
[PMID: 15629247]
56. Angra SK, Mohan M, Saini JS. Medical therapy of cataract
(evaluation of Catalin). Indian J Ophthalmol 1983; 31:5-8.
[PMID: 6354928]
57. Ito Y, Nagai N, Cai H, Takeda M, Koizumi Y. Preventive effect
of  eye  drops  of  liposomes  containing  disulfiram  and
cefmetazole on selenite-induced cataract in rat pups. J Oleo
Sci 2006; 55:15-22.
58. Sakthivel  M,  Geraldine  P,  Thomas  PA.  Alterations  in  the
lenticular  protein  profile  in  experimental  selenite-induced
cataractogenesis and prevention by ellagic acid. Graefes Arch
Clin Exp Ophthalmol. 2011 [PMID: 21455778]
59. Yan H, Harding JJ, Hui YN, Li MY. Decreased chaperone
activity of alpha-crystallin in selenite cataract may result from
selenite-induced aggregation. Eye (Lond) 2003; 17:637-45.
[PMID: 12855974]
60. Tamada Y, Fukiage C, Mizutani K, Yamaguchi M, Nakamura
Y,  Azuma  M,  Shearer  TR.  Calpain  inhibitor,  SJA6017,
reduces the rate of formation of selenite cataract in rats. Curr
Eye Res 2001; 22:280-5. [PMID: 11462167]
Molecular Vision 2011; 17:1862-1870 <http://www.molvis.org/molvis/v17/a203> © 2011 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 7 July 2011. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1870